Contraceptive Technology Update – June 1, 2007
June 1, 2007
View Issues
-
New data emerge from the WHI: How will they impact your practice?
Has your treatment of menopausal women changed since the initial findings released from the Women's Health Initiative (WHI) randomized, controlled trials of hormone therapy (HT)? Findings from a just-published secondary analysis of data from the WHI indicate that women who initiated HT closer to menopause tended to have reduced risk of coronary heart disease (CHD), while women further from menopause tended to have a slightly higher risk for the disease. -
New recommendations out for gonorrhea treatment
Update your practice when it comes to treatment of gonorrhea: The Centers for Disease Control and Prevention (CDC) no longer recommends the fluoroquinolone antibiotics ciprofloxacin, ofloxacin, and levofloxacin as a treatment for gonorrhea in the United States. -
What is next on the HPV vaccine horizon?
As clinicians begin to integrate use of the first cervical cancer vaccine (Gardasil, Merck & Co.; Whitehouse Station, NJ), the Food and Drug Administration (FDA) is set to review the application for a second vaccine. -
New recommendations out on HIV & circumcision
Global policies are being updated with the recent issuance of recommendations from an expert consultation on male circumcision for HIV prevention.1 But what impact do the recommendations have on your practice? -
Face facts about effectiveness of ECPs
In 1992, reproductive health advocates estimated that emergency contraceptive pills (ECPs) could prevent half of all unintended pregnancies and abortions in the United States each year. -
Update your practice when it comes to IUDs
Consider the following patients: a 15-year-old young mother, a 30-year-old married woman with no previous pregnancies, a 30-year-old single woman with no children, and a 30-year-old HIV-positive woman with three children. When discussing contraceptive options, do you include intrauterine contraception in talking with these women?